0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
This Week in JAMA |

This Week in JAMA FREE

JAMA. 2008;299(8):871. doi:10.1001/jama.299.8.871.
Text Size: A A A
Published online

TREATMENT OF ADOLESCENT SSRI-RESISTANT DEPRESSION

Selective serotonin reuptake inhibitors (SSRIs), psychotherapy, or both are recommended for the acute management of adolescents with depression. However, at least 40% of patients do not respond to initial treatment with these therapies, and evidence-based guidance for subsequent treatment is lacking. Brent and colleagues report results of a clinical trial in which adolescents with depression who had not responded to an initial 2-month treatment with an SSRI and had not received cognitive behavioral therapy (CBT) were randomly assigned to switch for 12 weeks to 1 of the following treatment strategies: (1) a second, different SSRI, (2) a different SSRI and CBT, (3) venlafaxine (a selective serotonin and noradrenergic reuptake inhibitor), or (4) venlafaxine and CBT. The authors found that the combination of switching to a different antidepressant agent and receiving CBT resulted in a higher rate of clinical response than switching only to a different medication. There was no difference in response to the medication switches, and patients who were switched to a different SSRI experienced fewer adverse effects than patients taking venlafaxine.

RISKS AND ERYTHROPOIESIS-STIMULATING AGENTS

Prior studies have documented an increased risk of venous thromboembolism (VTE) in patients with cancer-associated anemia who are treated with the erythropoiesis-stimulating agents (ESAs). In an updated investigation of safety concerns related to ESAs, Bennett and colleagues analyzed data from phase 3 clinical trials published or presented between January 1993 and January 2007 to assess ESA-associated risks of VTE and mortality. The authors report that anemic patients with cancer who were treated with ESAs had a 1.55-fold increased risk of VTE and a 1.10-fold increased risk of mortality compared with patients who received placebo or standard care.

NONEMBRYONIC STEM CELLS FOR NONMALIGNANT DISEASES

Investigation of the clinical applications of embryonic stem cells has been hampered by methodological and ethical challenges. In contrast, stem cells from peripheral or umbilical cord blood and bone marrow can be easily and safely harvested. Burt and colleagues reviewed the literature and surveyed investigators to examine patient outcomes and mortality associated with current clinical applications of blood-derived and bone marrow–derived stem cells for nonmalignant nonhematologic diseases. Their analysis suggests that stem cells harvested from blood or bone marrow may provide modest disease-ameliorating effects in selected patients with some autoimmune diseases and some cardiovascular disorders.

CLINICIAN'S CORNER
MALIGNANCY-ASSOCIATED SPINAL CORD COMPRESSION

Perspectives on Care at the Close of Life

Ms H is a 56-year-old woman who was diagnosed with breast cancer in 1986 and treated with mastectomy, chemotherapy, and chest wall radiotherapy. Bone metastases were initially diagnosed in 1990, and Ms H has received medical, surgical, and radiation therapy to treat these and subsequent bone metastases. Recently, she experienced pain and neurological symptoms from a recurrent metastatic tumor at the T6 and T7 vertebrae. Abrahm and colleagues discuss the diagnosis, treatment, and prognosis of malignant spinal cord compression.

A PIECE OF MY MIND

“Although ‘transfusion’ is not mentioned in the Bible, the relevant passages warn about the consequences of eating blood.” From “Listening to Leviticus.”

MEDICAL NEWS & PERSPECTIVES

A clinical trial testing a combination of 2 anticholesterol drugs (exetimibe/simvastatin, or Vytorin) is embroiled in controversy after results revealed that the therapy failed to prevent progression of atherosclerosis.

COMMENTARIES

The health care cost-coverage trade-off

Organize care to maximize health

Lessons from the ENHANCE trial

Environmental change and health

AUTHOR IN THE ROOM TELECONFERENCE

Join Stephen Shortell, PhD, on March 19, 2008, from 2 to 3 PM eastern time to discuss improving patient safety. To register, go to http://www.ihi.org/AuthorintheRoom.

READERS RESPOND

How would you manage a 74-year-old man who has moderate daily alcohol use, memory loss, and progressive neuropathy? Go to www.jama.com to read the case and submit your response. Your response may be selected for online publication. Submission deadline is February 27.

JAMA PATIENT PAGE

For your patients: Information about spinal stenosis.

First Page Preview

View Large
First page PDF preview

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.